By Sriparna Roy April 24 (Reuters) - Eli Lilly's newly launched weight-loss pill had a modest second week, analysts said on Friday, as competition with Danish rival Novo Nordisk heats up in the oral obesity drug market. The pill, launched earlier this month as Foundayo, was prescribed 3,707 times in the U.S. in the week ended April 17, IQVIA data shared by Wall Street analysts showed, up from 1,390 in its debut week. Novo's Wegovy pill, launched in January, had clocked 18,410 prescriptions in its second wee ...